Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIRVANA-1 in advanced ovarian cancer after complete cytoreductive surgery
jRCT2031220203Recruiting
- Sponsor
- Takeda
- Start
- Jan 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Randomised, open-label trial of niraparib, bevacizumab, paclitaxel and carboplatin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Takeda. Primary endpoint: Progression-free survival rate at 24 months. Started Jan 2023; status: recruiting.
02
Drugs
niraparibbevacizumabpaclitaxelcarboplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2031220203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220203.